Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.
New approach may ease problems with noncompliance, according to researchers.
Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results
Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.
Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.
Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.
Long-term hemodialysis (HD) patients who receive paricalcitol as treatment for secondary hyperparathyroidism (SHPT) may require less erythropoietin than those who receive no SHPT treatment, according to new data presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Although daily dosing of cinacalcet may be an optimal treatment for secondary hyperparathyroidism (SHPT) compared with other dosing regimens, thrice-weekly post-dialysis dosing may be a viable option when daily dosing is ineffective because of patient noncompliance or other factors.
Low serum 25-hydroxyvitamin D (25 D) levels may be playing a role in bone disease among renal transplant recipients, researchers reported here at the National Kidney Foundation’s Spring Clinical Meetings.
Monthly rather than quarterly monitoring of parathyroid hormone (PTH) may be better for chronic hemodialysis (HD) patients.
Please login or register first to view this content.
